Form 8-K for BLUEBIRD BIO, INC.
Other Events, Financial Statements and Exhibits
Item 8.01 Other Events
On December 14, 2016, bluebird bio, Inc. (“bluebird”) issued a press release announcing the treatment of the first subject in the Northstar-2 Study, bluebird’s global, multi-center Phase III study of its LentiGlobin product candidate for the treatment of patients with transfusion-dependent ?-thalassemia who do not have a ?0/?0 genotype.
The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press release issued by bluebird bio, Inc. on December 14, 2016.